Cryo-Cell International, Inc. (CCEL)

Over the past six months, Cryo-Cell International's stock has experienced a notable decline, decreasing by 52.13% between December 23, 2024, and December 19, 2025. The company paused its Q4 2025 dividend, after prior dividend payments. Despite the stock's decline, Co-CEO David Portnoy made open-market purchases of shares in August and November 2025. The company reported consolidated revenues of $7.83 million for the third quarter of fiscal 2025, which represented a 3% year-over-year dip.

While direct information on the seasonality of demand for Cryo-Cell International's products and services is not explicitly detailed, there are indications of seasonal patterns in the company's stock performance. Historical seasonal charts for CCEL suggest a period of seasonal strength for the stock, aligning with the broader Healthcare sector's seasonal strength. This suggests that while the underlying demand for cord blood and tissue banking might be relatively stable, the stock's market performance exhibits seasonal trends.

Cryo-Cell International, Inc. is a biotechnology company specializing in cellular processing and cryogenic storage, founded in 1989 as the world's first private cord blood bank. The company operates in the Healthcare sector, specifically in Healthcare Providers & Services and Medical - Care Facilities industries. Its major products and services include cord blood banking, involving the collection, processing, and long-term cryogenic storage of umbilical cord blood, cord tissue banking for the collection and storage of umbilical cord tissue, adipose tissue banking for the cryopreservation of fat tissue, and the PrepaCyte CB Processing System, a proprietary processing technology. The company's business model is largely subscription-based, with initial fees for collection and processing, followed by annual storage fees.

Cryo-Cell International has a significant global presence, serving over 500,000 parents across 87 countries. The company maintains a global network of collection sites and partnerships. Its services extend to numerous countries, including the United States, Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, India, Mexico, Nicaragua, Pakistan, Panama, Peru, the Dominican Republic, and Venezuela. The company's headquarters are located in Oldsmar, Florida, United States.

Cryo-Cell International maintains a strong brand reputation as an industry leader and the world's first private cord blood bank. The company's commitment to quality and scientific integrity is underscored by its FDA registration, AABB accreditation, and FACT accreditation. A significant positive event impacting its reputation is the exclusive, collaborative license agreement with Duke University, secured in February 2021, granting Cryo-Cell rights to intellectual property related to cord blood and cord tissue for cellular therapies.

Cryo-Cell International's ownership structure is characterized by a significant concentration among insiders and a presence of institutional investors. Insiders collectively own approximately 40.48% of the common stock, with David I. Portnoy being a dominant individual investor. Major institutional owners include Hamilton Lane Advisors LLC, SFI Advisors, LLC, and Vanguard Group Inc, among others.